At a glance
ClinicalIndex Comparison RecordN/ACompleted· 66 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Diagnostic, Transversal, Comparative, Not Randomized Trial for the Evaluation of Cystatin C as an Early Marker of Contrast-Medium Nephropathy in High-and-Intermedium-Risk Patients Undergoing to Cardiac Catheterization
In Brief
An observational study for Contrast Induced Nephropathy and Acute Renal Failure. Completed, enrolled 66 participants across 1 site.
Detailed Summary
Hypothesis: Cystatin C compared with creatinine is a better and earlier marker of contrast-induced nephropathy in high and intermedium risk cardiac catheterization patients. Primary Objective: Establish if Cystatin C is superior detecting contrast-induced nephropathy than creatinine in high and intermedium risk cardiac catheterization patients.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsContrast Induced Nephropathy, Acute Renal Failure
CountriesMexico
Collaborators--
Timeline
N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2006
First PostedApr 2007
Primary CompletionDec 2007
Study CompletionApr 2008
TodayJul 2026
First PostedApr 30, 2007
Enrollment StartDec 1, 2006
Primary CompletionDec 1, 2007
Study CompletionApr 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 19.2 years ago